|
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS |
Jun 2019 |
Current Hematologic Malignancy Report |
Myelodysplastic Syndromes (MDS) |
|
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis |
Jun 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial |
Jun 2019 |
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes |
May 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
The case for upfront HLA-matched unrelated donor HCT as a curative option for adult acquired severe aplastic anemia: Upfront MUD HCT for adult severe aplastic anemia |
May 2019 |
Biology of Blood and Marrow Transplantation: Journal of the American Society of Blood and Marrow Transplantation |
Aplastic Anemia |
|
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes |
May 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Management of myelodysplastic syndromes after failure of response to hypomethylating agents |
May 2019 |
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
|
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes |
Apr 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge |
Apr 2019 |
BMJ Case Reports |
Myelodysplastic Syndromes (MDS) |
|
Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis |
Apr 2019 |
Haemotologica |
Myelodysplastic Syndromes (MDS) |
